The Relationship of Obesity to Hospice Use and Expenditures A Cohort Study

John A. Harris, MD, MSc; Elena Byhoff, MD, MSc; Chithra R. Perumalswami, MD, MSc; Kenneth M. Langa, MD, PhD; Alexi A. Wright, MD, MPH; and Jennifer J. Griggs, MD, MPH

Background: Obesity complicates medical, nursing, and informal care in severe illness, but its effect on hospice use and Medicare expenditures is unknown.

Objective: To describe the associations between body mass index (BMI) and hospice use and Medicare expenditures in the last 6 months of life.

Design: Retrospective cohort.

Setting: The HRS (Health and Retirement Study).

Participants: 5677 community-dwelling Medicare fee-forservice beneficiaries who died between 1998 and 2012.

Measurements: Hospice enrollment, days enrolled in hospice, in-home death, and total Medicare expenditures in the 6 months before death. Body mass index was modeled as a continuous variable with a quadratic functional form.

Results: For decedents with BMI of 20 kg/m², the predicted probability of hospice enrollment was 38.3% (95% CI, 36.5% to 40.2%), hospice duration was 42.8 days (CI, 42.3 to 43.2 days), probability of in-home death was 61.3% (CI, 59.4% to 63.2%), and total Medicare expenditures were \$42.803 (CI, \$41.085 to \$44.521). When BMI increased to 30 kg/m², the predicted probability of hospice enrollment decreased by 6.7 percentage

points (CI, -9.3 to -4.0 percentage points), hospice duration decreased by 3.8 days (CI, -4.4 to -3.1 days), probability of in-home death decreased by 3.2 percentage points (CI, -6.0 to -0.4 percentage points), and total Medicare expenditures increased by \$3471 (CI, \$955 to \$5988). For morbidly obese decedents (BMI \geq 40 kg/m²), the predicted probability of hospice enrollment decreased by 15.2 percentage points (CI, -19.6 to -10.9 percentage points), hospice duration decreased by 4.3 days (CI, -5.7 to -2.9 days), and in-home death decreased by 6.3 percentage points (CI, -11.2 to -1.5 percentage points) versus decedents with BMI of 20 kg/m².

Limitation: Baseline data were self-reported, and the interval between reported BMI and time of death varied.

Conclusion: Among community-dwelling decedents in the HRS, increasing obesity was associated with reduced hospice use and in-home death and higher Medicare expenditures in the last 6 months of life.

Primary Funding Source: Robert Wood Johnson Foundation Clinical Scholars Program.

Ann Intern Med. 2017;166:381-389. doi:10.7326/M16-0749 Annals.org
For author affiliations, see end of text.

This article was published at Annals.org on 7 February 2017.

Seventy percent of U.S. adults aged 60 years or older are overweight or obese (1). Obesity is associated with shorter life expectancy, increased risk for hospitalization, and higher use of intensive care services (2-4), as well as variation in the quality of cancer screening, immunization, cancer care, and intensive care (4-8).

For obese persons, technical and logistical issues arise during hospitalizations, surgery, and end-of-life care that require special attention. Obesity challenges the ability of health care providers and caregivers to conduct thorough physical assessments, assist with mobility and self-care, recognize frailty and malnutrition, and perform certain indicated procedures (8-11). In addition, weight stigma has been found to modify patients' and providers' behaviors, potentially resulting in delayed diagnoses, suboptimal care, and weaker therapeutic alliances (12-15). To date, however, no studies have examined the association between obesity and hospice use, a cornerstone of end-of-life care.

To understand the effect of body mass index (BMI) on hospice use and Medicare expenditures at the end of life, we used the HRS (Health and Retirement Study) to examine hospice enrollment, days enrolled in hospice, decedents' place of death, and Medicare expenditures as a function of participant BMI, controlling for demographic, medical, functional, and geographic factors. In the context of the unique challenges to care for

obese persons, we hypothesized that higher BMI would be associated with decreased hospice use and fewer in-home deaths due to patient, provider, and system factors affecting referral to and enrollment in hospice services, and that higher BMI would be associated with increased health care expenditures due to increased use of hospital and health care services.

METHODS

Study Population

We examined survey and Medicare claims data for HRS participants who died between 1998 and 2012, the most recent data available (16). The HRS is a nationally representative panel survey that biennially interviews U.S. adults older than 50 years about health and financial issues. Since 1992, the HRS has enrolled more than 30 000 participants, with a follow-up response rate consistently greater than 90%; the recruitment and survey methods have been previously described (17). The HRS survey covers a wide range of personal- and household-level data, including detailed medical, economic, and social characteristics (16). We studied decedents who had previously consented to linkage of survey data with their Medicare claims data to give additional information on health care use and expenditures beyond HRS-collected data. Respondents were eligible for the current study if they had complete fee-

 $^{\circ}$ 2017 American College of Physicians 381

for-service Medicare Parts A and B claims data for the last 180 days of life. To focus on health care use among a community-dwelling population, we excluded respondents in nursing care facilities at the last survey wave. We also excluded respondents with missing information on BMI, survey date, marital status, geographic location, functional status, or cognitive function.

Outcomes

Participants with any Medicare hospice claims were considered hospice enrollees. For each patient, any day with a Medicare claim for hospice was counted as a day of hospice services (18). Using the Medicare Provider Analysis and Review claims files, we classified each day as at home (no facility claims) or in a facility (claims for hospital, skilled-nursing, or long-term acute care). We calculated total Medicare spending during the last 180 days of life across all domains in Medicare files (inpatient, outpatient, physician or supplier, durable medical, hospice, home health, and skilled nursing). Expenditures were adjusted to 2012 U.S. dollars using the medical component of the U.S. Bureau of Labor Statistics Consumer Price Index.

Other Variables

The primary independent variable of interest was BMI, which we calculated for each decedent using self-reported height and weight from the last survey interview before death. We defined the probable date of death using Medicare claims data linked to the National Death Index. Respondent-reported measures of sex, race (nonwhite races were collapsed due to sample size), Hispanic ethnicity, marital status (widowed, single, separated, divorced, or married), and total household assets (adjusted to 2012 U.S. dollars) were used.

We identified 28 comorbid medical conditions from 1 year before the defined end-of-life period (6 months before death) using International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), codes from Medicare claims (Elixhauser method [19]). We used measures for the number of limitations in activities of daily living (ADLs) and instrumental activities of daily living (IADLs) and for cognitive function (normal, mild cognitive impairment/cognitive impairment, no dementia, or dementia) (20). Decedents were linked with a measure of regional end-of-life expenditures (average Medicare expenditures in the last 6 months of life as reported in the 2012 Dartmouth Atlas of Health Care by hospital referral region, separated into quintiles), with each decedent's ZIP code linked to its corresponding hospital referral region (21).

Cause of death was determined from the National Death Index, which categorizes causes of death according to 113 ICD-10 codes. These codes were categorized as infectious, malignancy, diabetes mellitus, neurologic, cardiac, pulmonary, gastrointestinal or hepatobiliary, renal, or other. After the respondent's death, proxy informants (typically a surviving partner or adult children) are interviewed about the respondent's end-of-life care. To examine whether obese patients

were more likely to die unexpectedly, we used the exit interview question, "Was the death expected at about the time it occurred or was it unexpected?" Response options included "yes," "unsure," or "no"; the latter 2 (n = 14) were grouped as negative responses. The time between response to the last survey and death was calculated using the date of survey administration and the date of death from National Death Index data.

Statistical Analysis

We modeled hospice enrollment, days enrolled in hospice, in-home death, and Medicare expenditures using generalized linear models. The models used a binomial distribution and logit link for hospice enrollment and in-home death, a Poisson distribution and log link for total hospice days, and a gamma distribution and log link for expenditures. We examined possible models for the functional form of BMI included as a categorical variable (using National Institutes of Health obesity categories), a linear functional form, and a quadratic functional form based on theory and empirical evidence (see the Appendix, available at Annals.org) (22). We report findings from our final models using BMI fit as a quadratic functional form based on theory, previous evidence about how BMI should vary with each outcome, and comparisons of overall model fit as well as discrimination and calibration testing. Models controlled for age at death, sex, nonwhite race, Hispanic ethnicity, marital status, total household assets, comorbid illnesses (19), limitations in ADLs and IADLs, cognitive function, quintile of regional end-of-life expenditures, and year of death.

In sensitivity analyses, to explore the extent to which the association of BMI and the outcomes was influenced by the length of time between the collection of BMI information and death, the aforementioned model was changed to include an interaction term between BMI and the time from collection of self-reported height and weight to death (23). To explore the extent to which the association of BMI and the outcomes was influenced by cause of death and proxy-reported expected death, each of these terms was added separately to the model. We also fit models with BMI defined as a categorical variable. In addition, we repeated the analysis with the complete HRS cohort of deceased fee-for-service beneficiaries (including nursing home residents) to see whether selecting communitydwelling respondents biased the overall results.

We report each measure in terms of the mean predicted outcome (probability of hospice enrollment, days enrolled in hospice, probability of in-home death, and Medicare expenditures) at 5 BMI levels (20, 25, 30, 35, and 40 kg/m²) and significance testing using 95% Cls. The mean predicted outcome was estimated by the statistical model for a given BMI while holding all other covariates at known values (24). Probabilities were reported as the percentage chance of the outcome occurring (0% to 100%). If the 95% CI did not contain the null hypothesis value, the results were considered statistically significant. We used Stata, version

382 Annals of Internal Medicine • Vol. 166 No. 6 • 21 March 2017

14.0 (StataCorp), for all analyses, specifically the glm and margins commands.

Ethics

Informed consent was obtained from all participants in the HRS. The University of Michigan Institutional Review Board-Medical deemed this study of decedents to be exempt from institutional review board approval.

Role of the Funding Source

The Robert Wood Johnson Foundation, the U.S. Department of Veterans Affairs, the National Institute on Aging, and the National Cancer Institute provided

Table 1. Characteristics of Decedents, by BMI Category*


Characteristic			BMI Category		
	Underweight (<18.5 kg/m²) (n = 424)	Normal (18.5-24.9 kg/m²) (n = 2509)	Overweight (25-29.9 kg/m²) (n = 1763)	Obese (30-39.9 kg/m²) (n = 864)	Morbidly Obeso (≥40 kg/m²) (n =117)
Mean age at death (SD), y	83.6 (9.4)	82.3 (8.8)	79.9 (9.1)	76.8 (9.3)	72.1 (8.4)
Sex, n (%)					
Female	319 (75)	1285 (51)	723 (41)	462 (53)	77 (66)
Male	105 (25)	1224 (49)	1040 (59)	402 (47)	40 (34)
Race, n (%)					
White	345 (81)	2128 (85)	1448 (82)	673 (78)	82 (70)
Black	≤70 (≤17)	316 (13)	257 (15)	164 (19)	≤30 (≤25)
Other	≤10 (≤2)	65 (3)	58 (3)	27 (3)	≤10 (≤9)
Fabruician or (9/1)					
Ethnicity, n (%)	400 (04)	2204 (OE)	1424 (02)	904 (02)	-110/-04\
Non-Hispanic	400 (94)	2384 (95)	1626 (92)	804 (93)	≤110 (≤94)
Hispanic	24 (6)	125 (5)	137 (8)	60 (7)	≤10 (≤9)
Marital status, n (%)					
Married/partnered	134 (32)	1173 (47)	962 (55)	459 (53)	58 (50)
Widowed	237 (56)	1062 (42)	603 (34)	303 (35)	33 (28)
Separated/divorced	32 (8)	204 (8)	154 (9)	74 (9)	≤20 (≤16)
Never married	21 (5)	70 (3)	44 (3)	28 (3)	≤10 (≤9)
Median total household assets (IQR), thousand \$	94 (8-295)	135 (26-422)	133 (27-347)	99 (9-303)	42 (3-123)
Chronic disease, n (%)					
Hypertension†	210 (50)	1392 (55)	1067 (61)	564 (65)	81 (69)
Diabetes‡	44 (10)	517 (21)	564 (32)	400 (46)	70 (60)
Congestive heart failure	113 (27)	689 (27)	517 (29)	294 (34)	52 (44)
Chronic pulmonary disease	154 (36)	682 (27)	500 (28)	265 (31)	47 (40)
Metastatic cancer	19 (4)	147 (6)	143 (8)	61 (7)	≤10 (≤9)
Weight loss	67 (16)	200 (8)	79 (4)	41 (5)	≤10 (≤7)
Complete for all and (0/)					
Cognitive function, n (%) Normal	1.47 (25)	1027 (41)	070 (40)	4/4/54)	/F/F/\
	147 (35)	1026 (41)	870 (49)	464 (54)	65 (56)
Mild cognitive impairment/cognitive impairment or no dementia	123 (29)	799 (32)	527 (30)	247 (29)	36 (31)
Dementia .	154 (36)	684 (27)	366 (21)	153 (18)	16 (14)
Functional status					
Activities of daily living					
No limitations, n (%)	125 (29)	1148 (46)	857 (49)	368 (43)	24 (21)
Mean limitations (SD), n	2.2 (2.2)	1.5 (1.9)	1.4 (1.8)	1.6 (1.9)	2.5 (1.9)
Instrumental activities of daily living	۷.۷ (۷.۷)	1.3 (1.7)	1.4 (1.0)	1.0 (1.7)	2.3 (1.7)
No limitations, <i>n</i> (%)	158 (37)	1346 (54)	1075 (61)	503 (58)	47 (40)
Mean limitations (SD), n	1.7 (1.8)	1.2 (1.7)	1.0 (1.5)	1.0 (1.4)	1.2 (1.4)
Quintile of regional end-of-life expenditures, n (%)					
Highest	111 (26)	774 (31)	523 (30)	226 (26)	28 (24)
Lowest	59 (14)	344 (14)	242 (14)	143 (17)	19 (16)
Madian time from galf was and d	11/05 17	1 2 (0 4 1 0)	1 4 (0 0 1 0)	1 2 (0 7 1 0)	1 4 (0 0 1 0)
Median time from self-reported height and weight to death (IQR), y	1.1 (0.5-1.7)	1.2 (0.6-1.9)	1.4 (0.8-1.9)	1.3 (0.7-1.9)	1.4 (0.8-1.9)

BMI = body mass index; IQR = interquartile range. * Reported at last survey interview. Values based on \leq 10 participants were assigned a value of \leq 10 because of privacy restrictions. In the case of a single cell in a column being suppressed, the cells with the second- and/or third-lowest counts were also assigned a value of less than the nearest multiple of 10 to prevent the ability to calculate the value of the suppressed cell.

† Defined as Elixhauser diagnosis of uncomplicated and/or complicated hypertension.

‡ Defined as Elixhauser diagnosis of uncomplicated and/or complicated diabetes.

Figure. Predicted probability of hospice enrollment, predicted total hospice days, predicted probability of in-home death, and predicted total Medicare expenditures in the last 6 mo of life, as a function of participant BMI.



Results are adjusted for decedent age, race/ethnicity, marital status, 28 Elixhauser medical conditions, total household assets, number of activities of daily living, number of instrumental activities of daily living, cognitive function (normal, mild cognitive impairment/cognitive impairment, no dementia, or dementia), quintile of regional end-of-life expenditures, and year of death. Shaded areas represent 95% Cls. BMI = body mass index.

financial support to the authors. The funding sources had no role in the design or conduct of the study, analysis or interpretation of the data, or approval of the manuscript.

RESULTS

Of 9859 HRS decedents who consented to linkage of survey data with Medicare claims data, 2485 with any managed care enrollment during the last 6 months of life were excluded. We also excluded 1352 decedents who reported living in a nursing facility at the last survey wave and participants with missing information from the last survey on date of the survey (n = 88), height or weight (n = 93), ZIP code (n = 23), marital status (n = 3), ADLs (n = 41), or cognitive function (n = 97) (Appendix Figure, available at Annals.org).

The final cohort included 5677 decedents. Of these, 424 (7%) were underweight (BMI <18.5 kg/m²), 2509 (44%) were of normal weight (BMI of 18.5 to 24.9 kg/m²), 1763 (31%) were overweight (BMI of 25 to 29.9 kg/m²), 864 (15%) were obese (BMI of 30 to 39.9 kg/m²), and 117 (2%) were morbidly obese (BMI \geq 40 kg/m²); the median BMI was 24.7 kg/m² (interquartile range [IQR], 21.5 to 28.2 kg/m²). The median age at death was 81.2 years (IQR, 73.8 to 87.5 years), and the median time from the last respondent survey to death was 15.6 months (IQR, 8.2 to 22.6 months). Sample

characteristics by BMI category are reported in Table 1. A complete description of all medical comorbidities by BMI category is reported in Appendix Table 1 (available at Annals.org).

The overall observed incidence of hospice enrollment was 34.7%. Participants with higher BMI had a significantly lower likelihood of hospice enrollment than those with a BMI of 20 kg/m² (Figure). Participants with a BMI of 40 kg/m² had a predicted probability of hospice enrollment of 23.1% (95% CI, 19.5% to 26.7%), whereas those with a BMI of 20 kg/m² had a predicted probability of 38.3% (CI, 36.5% to 40.2%) (Table 2). Among those who enrolled in hospice care, the predicted total hospice days decreased as BMI increased. Participants with a BMI of 40 kg/m² spent 4.3 fewer days (CI, -5.7 to -2.9 days) in hospice care than those with a BMI of 20 kg/m². This effect was driven by decreased numbers of days spent in home hospice care, and we found no clinically significant increase in facility hospice care for obese patients (Appendix Table 2, available at Annals.org).

The overall observed incidence of in-home death was 59.6%. Participants with higher BMI had a significantly lower likelihood of in-home death than those with a BMI of 20 kg/m² (Figure). Participants with a BMI of 40 kg/m² had a predicted probability of in-home death of 55.0% (CI, 51.0% to 58.9%), whereas those

384 Annals of Internal Medicine • Vol. 166 No. 6 • 21 March 2017

Annals.org

with a BMI of 20 kg/m² had a predicted probability of 61.3% (CI, 59.4% to 63.2%) (**Table 2**).

In the last 6 months of life, total predicted Medicare expenditures increased as BMI increased. The mean total predicted expenditures were \$42 803 (CI, \$41 085 to \$44 521) (Table 2) for participants with a BMI of 20 kg/m² and were \$3471 (CI, \$955 to \$5988) higher for those with a BMI of 30 kg/m². Predicted expenditures for those with a BMI of 30, 35, or 40 kg/m² were constant, but there was also a decrease in precision related to small sample size at the upper extreme of the sample's BMI range (Figure). The component Medicare expenditures were driven by inpatient, outpatient, and physician or supplier expenditures that increased by a mean of \$4343 (CI, \$2008 to \$6678) for decedents with a BMI of 30 kg/m² versus those with a BMI of 20 kg/m². However, these were offset by lower home health, durable medical, and hospice Medicare expenditures, which decreased by a mean of \$1173 (CI, \$659 to \$1688) for decedents with a BMI of 30 kg/m² versus those with a BMI of 20 kg/m². Because of differences in both enrollment and length of stay, predicted hospice Medicare expenditures for participants with a BMI of 40 kg/m² (\$1321 [CI, \$949 to \$1692]) were 60% lower than for those with a BMI of 20 kg/m² (\$3357 [CI, \$2896 to \$3818]) (Table 3).

To examine whether this analysis was confounded by cause of death or proxy-reported expected death, we refit the model with these variables included. Diabetes- and renal-related causes of death were more common for obese and morbidly obese respondents than for those with normal BMI (18.5 to 24.9 kg/m²) (Appendix Table 3, available at Annals.org). When we included the decedent's cause of death as a covariate,

we observed trends and effect sizes that were consistent with the results from the original model (Appendix Table 4, available at Annals.org). The likelihood that a proxy reported the death as "expected" decreased as BMI increased: 55% of deaths were expected by proxies for normal-weight participants compared with 45% for morbidly obese participants (Appendix Table 3). When we included expected death as a model covariate, the effect sizes also remained stable (Appendix Table 4). When we included an interaction term between BMI and time from survey data collection, the trends and effect sizes of the outcomes were similar (Appendix Table 4).

The main outcomes are reported by BMI categories in Appendix Tables 5 and 6 (available at Annals .org), and the trends and effect sizes of the outcomes were similar to when BMI was modeled as a continuous variable. The main outcomes with nursing home residents included were similar to those in the community-dwelling cohort and are presented in Appendix Table 7 (available at Annals.org). The coefficients, SEs, and constants for the model predicting hospice enrollment are shown in Appendix Table 8 (available at Annals .org).

DISCUSSION

In this large national sample of older American decedents, we found that increased BMI was independently associated with decreased hospice enrollment, duration of hospice services, and in-home death and increased Medicare expenditures in the last 6 months of life, after adjustment for key sociodemographic, medical, functional status, and geographic factors. In-

Table 2. Predicted Probability of Hospice Enrollment, Total Hospice Days, Probability of In-Home Death, and Total Medicare Expenditures, by BMI (n = 5677)*

Outcome			ВМІ		
	20 kg/m ²	25 kg/m ²	30 kg/m ²	35 kg/m ²	40 kg/m²
Predicted probability of hospice enrollment, %	38.3 (36.5 to 40.2)	35.3 (34.0 to 36.7)	31.7 (30.0 to 33.4)	27.5 (25.2 to 30.0)	23.1 (19.5 to 26.7)
Difference vs. BMI of 20 kg/m ²	Reference	-3.0 (-4.7 to -1.3)	-6.7 (-9.3 to -4.0)	-10.8 (-14.2 to -7.5)	-15.2 (-19.6 to -10.9)
Predicted total hospice days†	42.8 (42.3 to 43.2)	40.4 (40.1 to 40.8)	39.0 (38.5 to 39.4)	38.3 (37.6 to 39.0)	38.5 (37.2 to 39.7)
Difference vs. BMI of 20 kg/m ²	Reference	-2.3 (-2.8 to -1.9)	−3.8 (−4.4 to −3.1)	-4.4 (-5.3 to -3.5)	-4.3 (-5.7 to -2.9)
Predicted probability of in-home death, %	61.3 (59.4 to 63.2)	59.7 (58.3 to 61.1)	58.1 (56.2 to 60.0)	56.5 (53.9 to 59.2)	55.0 (51.0 to 58.9)
Difference vs. BMI of 20 kg/m ²	Reference	-1.6 (-3.3 to 0.1)	-3.2 (-6.0 to -0.4)	-4.8 (-8.5 to -1.1)	-6.3 (-11.2 to -1.5)
Predicted total end-of-life expenditures, \$	42 803 (41 085 to 44 521)	45 011 (43 712 to 46 311)	46 274 (44 542 to 48 007)	46 508 (44 147 to 48 870)	45 698 (42 235 to 49 161)
Difference vs. BMI of 20 kg/m ²	Reference	2208 (718 to 3698)	3471 (955 to 5988)	3705 (424 to 6986)	2895 (-1342 to 7132)

BMI = body mass index.

^{*} Predicted outcomes were calculated for representative BMI values and were adjusted for decedent age, race/ethnicity, marital status, 28 Elix-hauser medical conditions, total household assets, number of activities of daily living and instrumental activities of daily living, cognitive function (normal, mild cognitive impairment/cognitive impairment, no dementia, or dementia), quintile of regional end-of-life expenditures, and year of death. Values are means (95% CIs).

[†] Among decedents who were ever enrolled in hospice (n = 1971).

Table 3. Predicted End-of-Life Component Medicare Expenditures, by BMI*

Component			ВМІ		
	20 kg/m ²	25 kg/m ²	30 kg/m ²	35 kg/m ²	40 kg/m²
Inpatient	23 051 (21 713 to 24 390)	24 828 (23 786 to 25 871)	25 973 (24 586 to 27 361)	26 389 (24 495 to 28 284)	26 041 (23 254 to 28 828)
Difference vs. BMI of 20 kg/m ²	Reference	1777 (632 to 2921)	2922 (962 to 4882)	3337 (758 to 5918)	2990 (-375 to 6354)
Outpatient	2845 (2570 to 3119)	3170 (2938 to 3402)	3239 (2965 to 3514)	3036 (2703 to 3368)	2608 (2213 to 3004)
Difference vs. BMI of 20 kg/m ²	Reference	325 (133 to 517)	395 (52 to 738)	191 (-253 to 635)	-236 (-751 to 279)
Physician/ supplier	7314 (6990 to 7638)	7955 (7705 to 8206)	8392 (8055 to 8728)	8584 (8117 to 9052)	8516 (7830 to 9202)
Difference vs. BMI of 20 kg/m ²	Reference	642 (369 to 914)	1078 (604 to 1552)	1271 (638 to 1903)	1202 (376 to 2029)
Home health and durable medical equipment	2636 (2402 to 2871)	2445 (2270 to 2619)	2321 (2125 to 2518)	2257 (2016 to 2498)	2248 (1895 to 2601)
Difference vs. BMI of 20 kg/m ²	Reference	-192 (-374 to -10)	−315 (−597 to −33)	-379 (-729 to -29)	-388 (-837 to 60)
Skilled nursing	4155 (3705 to 4607)	4347 (3961 to 4733)	4519 (3989 to 5049)	4668 (3945 to 5390)	4791 (3736 to 5845)
Difference vs. BMI of 20 kg/m ²	Reference	192 (-204 to 587)	364 (-311 to 1038)	512 (-388 to 1413)	635 (-570 to 1840)
Hospice	3357 (2896 to 3818)	3036 (2670 to 3403)	2514 (2168 to 2860)	1905 (1578 to 2231)	1321 (949 to 1692)
Difference vs. BMI of 20 kg/m ²	Reference	-320 (-681 to 40)	-843 (-1347 to -339)	-1452 (-2007 to -898)	-2036 (-2633 to -1439)

BMI = body mass index

creasing BMI was associated with higher expenditures for inpatient, outpatient, and physician claims, although these were partially offset by lower hospice, durable medical equipment, and skilled-nursing expenditures in this community-dwelling population. Obesity was a risk factor for lower-quality end-of-life care, which we defined as enrollment in hospice, longer length of hospice stay, and in-home death. Additional research should focus on the mechanisms underlying this vulnerability at the end of life.

In this study, we showed that higher BMI was a strong negative predictor of hospice enrollment; the predicted probability of hospice enrollment was 40% lower for decedents with a BMI of 40 kg/m² than for those with a BMI of 20 kg/m². Hospice enrollment has previously been shown to vary by sex, race, ethnicity, primary diagnosis, location before enrollment, referring physician, patient preferences with regard to lifesustaining treatment, and site of death (25-30), but this is, to our knowledge, the first study to identify obesity as an independent risk factor for disparity in the use of hospice services. Previous studies have shown that hospice use is associated with improved quality of care for patients and their families, with reduced psychiatric morbidity and increased ratings of perceived health care quality in bereaved caregivers (31-36), heightening concerns about the effect of underuse of hospice care in this population (33, 37, 38).

We hypothesize that obesity may affect hospice enrollment through 2 mechanisms: referral behaviors and enrollment policies. First, prolonged cachexia experienced by some persons at the end of life is recognized by family members and physicians as being closely related to the dying process (39). Those who do not experience profound cachexia may be less likely to be recognized as appropriate referrals for palliative or hospice services by providers compared with more cachectic persons, who may appear less physically robust. The trajectories of illness and dying may vary as a function of patient obesity within diseases. Obese patients may have a more sudden decline in performance status or increase in metabolic abnormalities, which may lead to more sudden deaths than in nonobese patients. In this study, the effect of obesity was not substantially moderated by whether the death was expected or the cause of death was known. However, little research is available on the association between trajectories of illness and obesity, and this may be an important factor in the provision of high-quality end-oflife health care.

Second, enrollment policies vary among hospice services, and some restrict access to care for persons with higher-cost medical needs (27). Obese patients in home hospice care may require increased nursing assistance, including mechanical lift devices to provide proper positioning and personal care in the terminal

386 Annals of Internal Medicine • Vol. 166 No. 6 • 21 March 2017

Annals.org

^{*} Predicted expenditures were calculated for representative BMI values and were adjusted for decedent age, race/ethnicity, marital status, 28 Elixhauser medical conditions, total household assets, number of activities of daily living and instrumental activities of daily living, cognitive function (normal, mild cognitive impairment/cognitive impairment, no dementia, or dementia), quintile of regional end-of-life expenditures, and year of death. Values are means (95% CIs) presented in U.S. dollars.

phase of dying (10). The need for extra nursing personnel or mechanical lifts may make home hospice care infeasible for obese patients and their caregivers (40).

Obesity is associated with increased use of health care services and associated expenditures (41-44). For obese participants in this community-dwelling cohort, we found that inpatient, outpatient, and physician Medicare expenditures were 13% higher (a difference of \$4343), but hospice, home health, and durable medical equipment expenditures were 20% lower (a difference of \$1173). Increased expenditures for obese persons have been attributed to the relatively increased prevalence of medical conditions, such as diabetes, hypertension, and coronary artery disease (45-47). However, higher BMI presents many challenges to medical management beyond increased medical multimorbidity. It is associated with decreased access to medical care, increased difficulty managing medical issues in an outpatient setting versus an inpatient setting, and more challenges in transitioning from inpatient care back to home care (48-52). Finally, there is an established record of negative provider attitudes and implicit bias against obese persons, and these attitudes may continue to influence care for obese persons at the end of life (13, 14). Each of these factors may impede the provision of optimal medical, nursing, and supportive care for obese persons, either independently or together, thus explaining the independent effect of obesity on end-of-life health care expenditures.

Our study has several potential limitations. We used a self-reported BMI measure that was collected a median of 16 months before death, and the time from collection of this biometric to death varied within the study cohort. A sensitivity analysis examining whether this interval affected the association between BMI and the outcomes showed that this was not substantial and did not change the overall effect. We examined only community-dwelling adults using fee-for-service Medicare claims, but our results did not differ significantly when nursing home residents were included in the sample. The sample did not include respondents who were enrolled in managed care Medicare plans; this group may have substantially different characteristics and resource use at the end of life, which may limit the generalizability of these results (53). Although we controlled for the presence of more than 2 dozen medical conditions, functional status (limitations in ADLs and IADLs and cognitive function) at the last core survey interview, cause of death, and the proxy informant's judgment of whether the death was expected, residual confounding may have inadequately controlled for differences in medical conditions and trajectories of illness that are affected by obesity.

These potential limitations notwithstanding, this study identified a significant relationship in decedents between obesity and decreased probability of hospice enrollment and in-home death, as well as fewer days of hospice care among those who were enrolled. The consequences of obesity for health care use and expenditures are substantial, and obese persons are vulnerable to suboptimal end-of-life care. As stakeholders

look for opportunities to improve the value of care by increasing quality and decreasing low-value services, the disparities in hospice use and Medicare expenditures by patient BMI provide an excellent opportunity for improvement. Policy interventions could include increased reimbursement for home care services of obese patients who require multiple support personnel, reimbursement for patient lifts and other special durable medical equipment in health care facilities, or concurrent palliative care for select patients with severe obesity. All people—regardless of body size—and their families should have equal opportunities to experience the benefits of high-quality end-of-life health care.

From University of Michigan, Ann Arbor, Michigan, and Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Acknowledgment: The authors thank Theodore J. Iwashyna, MD, PhD, Associate Professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, for conceptual guidance; Ryan McCammon, MS, at the Institute for Social Research, University of Michigan, for programming assistance; and HwaJung Choi, PhD, Assistant Research Scientist, Division of General Medicine, Department of Internal Medicine, University of Michigan, for review of statistical programming and methods.

Financial Support: The Health and Retirement Study is funded by the National Institute on Aging (U01 AG009740) and performed at the Institute for Social Research, University of Michigan. Drs. Harris and Byhoff were supported by the Robert Wood Johnson Foundation at the time the manuscript was originally submitted. Dr. Byhoff was supported by the U.S. Department of Veterans Affairs. Dr. Perumalswami is supported by the Robert Wood Johnson Foundation and the U.S. Department of Veterans Affairs. Dr. Langa is supported by the U.S. Department of Veterans Affairs and the National Institute on Aging (P30 AG024824). Dr. Wright is supported by the National Cancer Institute (K07 CA166210).

Disclosures: Dr. Langa reports grants from the National Institute on Aging during the conduct of the study and outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms .do?msNum=M16-0749.

Reproducible Research Statement: Study protocol and data set: Not available. Statistical code: Available from Dr. Harris (e-mail, harrisja@mail.magee.edu).

Requests for Single Reprints: John A. Harris, MD, MSc, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, 300 Halket Street, Suite 2328, Pittsburgh, PA 15213; e-mail, harrisja@mail.magee.edu.

Current author addresses and author contributions are available at Annals.org.

able at 7 timals.org.

Annals of Internal Medicine • Vol. 166 No. 6 • 21 March 2017 387

References

- 1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of child-hood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806-14. [PMID: 24570244] doi:10.1001/jama.2014.732
- 2. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289:187-93. [PMID: 12517229]
- 3. Hauck K, Hollingsworth B. The impact of severe obesity on hospital length of stay. Med Care. 2010;48:335-40. [PMID: 20220534] doi: 10.1097/MLR.0b013e3181ca3d85
- 4. Prescott HC, Chang VW, O'Brien JM Jr, Langa KM, Iwashyna TJ. Obesity and 1-year outcomes in older Americans with severe sepsis. CritCare Med. 2014;42:1766-74. [PMID: 24717466] doi:10.1097/CCM .000000000000336
- 5. Maruthur NM, Bolen S, Brancati FL, Clark JM. Obesity and mammography: a systematic review and meta-analysis. J Gen Intern Med. 2009;24:665-77. [PMID: 19277790] doi:10.1007/s11606-009-0939-3
- 6. Maruthur NM, Bolen SD, Brancati FL, Clark JM. The association of obesity and cervical cancer screening: a systematic review and meta-analysis. Obesity (Silver Spring). 2009;17:375-81. [PMID: 18997682] doi:10.1038/oby.2008.480
- 7. Harris JA, Moniz MH, lott B, Power R, Griggs JJ. Obesity and the receipt of influenza and pneumococcal vaccination: a systematic review and meta-analysis. BMC Obes. 2016;3:24. [PMID: 27200179] doi:10.1186/s40608-016-0105-5
- 8. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267-73. [PMID: 15956006]
- Gupta D. Moribund obesity as a palliative care diagnosis [Letter].
 J Palliat Med. 2009;12:515-6. [PMID: 19508135] doi:10.1089/jpm.2009.0043
- 10. Nwosu AC, Raj J, Hugel H. Palliative care and obesity: are we prepared? [Letter]. J Palliat Med. 2012;15:7-8. [PMID: 22268403] doi: 10.1089/jpm.2011.0333
- 11. Broome CA, Ayala EM, Georgeson KA, Heidrich SM, Karnes K, Wells JB. Nursing care of the super bariatric patient: challenges and lessons learned. Rehabil Nurs. 2015;40:92-9. [PMID: 25044311] doi: 10.1002/rnj.165
- 12. Puhl R, Brownell KD. Bias, discrimination, and obesity. Obes Res. 2001;9:788-805. [PMID: 11743063]
- 13. Puhl RM, Heuer CA. Obesity stigma: important considerations for public health. Am J Public Health. 2010;100:1019-28. [PMID: 20075322] doi:10.2105/AJPH.2009.159491
- 14. Budd GM, Mariotti M, Graff D, Falkenstein K. Health care professionals' attitudes about obesity: an integrative review. Appl Nurs Res. 2011;24:127-37. [PMID: 20974067] doi:10.1016/j.apnr.2009.05.001 15. Huizinga MM, Cooper LA, Bleich SN, Clark JM, Beach MC. Physician respect for patients with obesity. J Gen Intern Med. 2009;24: 1236-9. [PMID: 19763700] doi:10.1007/s11606-009-1104-8
- 16. Kelley AS, Langa KM, Smith AK, Cagle J, Ornstein K, Silveira MJ, et al. Leveraging the Health and Retirement Study to advance palliative care research. J Palliat Med. 2014;17:506-11. [PMID: 24694096] doi:10.1089/jpm.2013.0648
- 17. Sonnega A, Faul JD, Ofstedal MB, Langa KM, Phillips JW, Weir DR. Cohort profile: the Health and Retirement Study (HRS). Int J Epidemiol. 2014;43:576-85. [PMID: 24671021] doi:10.1093/ije/dyu067 18. Teno JM, Gozalo PL, Bynum JP, Leland NE, Miller SC, Morden NE, et al. Change in end-of-life care for Medicare beneficiaries: site of death, place of care, and health care transitions in 2000, 2005, and 2009. JAMA. 2013;309:470-7. [PMID: 23385273] doi:10.1001/jama.2012.207624
- 19. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27. [PMID: 9431328]
- 20. Crimmins EM, Kim JK, Langa KM, Weir DR. Assessment of cognition using surveys and neuropsychological assessment: the Health and Retirement Study and the Aging, Demographics, and Memory Study. J Gerontol B Psychol Sci Soc Sci. 2011;66 Suppl 1:i162-71. [PMID: 21743047] doi:10.1093/geronb/gbr048

- 21. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003;138:273-87. [PMID: 12585825] doi:10.7326/0003-4819-138-4-200302180-00006
- 22. Wong ES, Wang BC, Garrison LP, Alfonso-Cristancho R, Flum DR, Arterburn DE, et al. Examining the BMI-mortality relationship using fractional polynomials. BMC Med Res Methodol. 2011;11:175. [PMID: 22204699] doi:10.1186/1471-2288-11-175
- 23. Alley DE, Metter EJ, Griswold ME, Harris TB, Simonsick EM, Longo DL, et al. Changes in weight at the end of life: characterizing weight loss by time to death in a cohort study of older men. Am J Epidemiol. 2010;172:558-65. [PMID: 20682520] doi:10.1093/aje/kwq168
- 24. StataCorp. Margins command. In: Stata 14 Base Reference Manual. College Station, TX: Stata Pr; 2015:1359-414.
- 25. Miesfeldt S, Murray K, Lucas L, Chang CH, Goodman D, Morden NE. Association of age, gender, and race with intensity of end-of-life care for Medicare beneficiaries with cancer. J Palliat Med. 2012;15: 548-54. [PMID: 22468739] doi:10.1089/jpm.2011.0310
- 26. Han B, Remsburg RE, Iwashyna TJ. Differences in hospice use between black and white patients during the period 1992 through 2000. Med Care. 2006;44:731-7. [PMID: 16862034]
- 27. Aldridge Carlson MD, Barry CL, Cherlin EJ, McCorkle R, Bradley EH. Hospices' enrollment policies may contribute to underuse of hospice care in the United States. Health Aff (Millwood). 2012;31: 2690-8. [PMID: 23213153] doi:10.1377/hlthaff.2012.0286
- 28. Obermeyer Z, Powers BW, Makar M, Keating NL, Cutler DM. Physician characteristics strongly predict patient enrollment in hospice. Health Aff(Millwood). 2015;34:993-1000. [PMID: 26056205] doi: 10.1377/hlthaff.2014.1055
- 29. Casarett D, Van Ness PH, O'Leary JR, Fried TR. Are patient preferences for life-sustaining treatment really a barrier to hospice enrollment for older adults with serious illness? J Am Geriatr Soc. 2006;54: 472-8. [PMID: 16551315]
- 30. Park NS, Carrion IV, Lee BS, Dobbs D, Shin HJ, Becker MA. The role of race and ethnicity in predicting length of hospice care among older adults. J Palliat Med. 2012;15:149-53. [PMID: 22313431] doi: 10.1089/jpm.2011.0220
- 31. Teno JM, Clarridge BR, Casey V, Welch LC, Wetle T, Shield R, et al. Family perspectives on end-of-life care at the last place of care. JAMA. 2004;291:88-93. [PMID: 14709580]
- 32. Teno JM, Shu JE, Casarett D, Spence C, Rhodes R, Connor S. Timing of referral to hospice and quality of care: length of stay and bereaved family members' perceptions of the timing of hospice referral. J Pain Symptom Manage. 2007;34:120-5. [PMID: 17583469]
- 33. Institute of Medicine. Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life. Washington, DC: National Academies Pr; 2014.
- 34. Wright AA, Zhang B, Ray A, Mack JW, Trice E, Balboni T, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008;300:1665-73. [PMID: 18840840] doi:10.1001/jama.300.14.1665
- 35. Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol. 2010;28:4457-64. [PMID: 20837950] doi:10.1200/JCO.2009.26.3863
- 36. Wright AA, Keating NL, Ayanian JZ, Chrischilles EA, Kahn KL, Ritchie CS, et al. Family perspectives on aggressive cancer care near the end of life. JAMA. 2016;315:284-92. [PMID: 26784776] doi:10.1001/jama.2015.18604
- 37. **Gazelle G.** Understanding hospice—an underutilized option for life's final chapter. N Engl J Med. 2007;357:321-4. [PMID: 17652645] 38. **Stevenson DG.** Growing pains for the Medicare hospice benefit. N Engl J Med. 2012;367:1683-5. [PMID: 23113479] doi:10.1056/NEJMp1208465

- 39. Boyd K, Murray SA. Recognising and managing key transitions in end of life care. BMJ. 2010;341:c4863. [PMID: 20847023] doi:10.1136/bmj.c4863
- 40. Varney S. Scaling up. The New York Times. 15 December 2015: D1. 41. Durden ED, Huse D, Ben-Joseph R, Chu BC. Economic costs of obesity to self-insured employers. J Occup Environ Med. 2008;50: 991-7. [PMID: 18784546] doi:10.1097/JOM.0b013e318182f730
- 42. Quesenberry CP Jr, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med. 1998;158:466-72. [PMID: 9508224]
- 43. Dee A, Kearns K, O'Neill C, Sharp L, Staines A, O'Dwyer V, et al. The direct and indirect costs of both overweight and obesity: a systematic review. BMC Res Notes. 2014;7:242. [PMID: 24739239] doi: 10.1186/1756-0500-7-242
- 44. Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ. 2012;31:219-30. [PMID: 22094013] doi:10.1016/j.jhealeco.2011.10.003
- 45. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-9. [PMID: 12503980]
- 46. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-7. [PMID: 17167477]

- 47. Franks PW, Hanson RL, Knowler WC, Sievers ML, Bennett PH, Looker HC. Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med. 2010;362:485-93. [PMID: 20147714] doi:10.1056/NEJMoa0904130
- 48. Goodell TT. The obese trauma patient: treatment strategies. J Trauma Nurs. 1996;3:36-44. [PMID: 9025456]
- 49. Gallagher SM. Restructuring the therapeutic environment to promote care and safety for the obese patient. J Wound Ostomy Continence Nurs. 1999;26:292-7. [PMID: 10865613]
- 50. King DR, Velmahos GC. Difficulties in managing the surgical patient who is morbidly obese. Crit Care Med. 2010;38:S478-82. [PMID: 20724881] doi:10.1097/CCM.0b013e3181ec54f6
- 51. Chong HS, Bell RL. Postoperative care of the obese patient. In: El Solh AA, ed. Critical Care Management of the Obese Patient. Hoboken, NJ: Wiley-Blackwell; 2012:147-58.
- 52. Phillips J. Care of the bariatric patient in acute care. J Radiol Nurs. 2013;32:21-31.
- 53. Byhoff E, Harris JA, Ayanian JZ. Characteristics of decedents in Medicare Advantage and traditional Medicare. JAMA Intern Med. 2016;176:1020-3. [PMID: 27273237] doi:10.1001/jamainternmed.2016.2266

IN THE CLINIC

In the Clinic is a monthly feature in *Annals* that focuses on practical management of patients with common clinical conditions. It offers evidence-based answers to frequently asked questions about screening, prevention, diagnosis, therapy, and patient education and provides physicians with tools to improve the quality of care. In the Clinic includes CME quizzes offering category 1 CME credit.

For more information on In the Clinic and to read the latest issue, visit www.annals.org/aim/in-the-clinic.

Current Author Addresses: Dr. Harris: Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, 300 Halket Street, Suite 2328, Pittsburgh, PA 15213

Drs. Byhoff and Perumalswami: Institute for Healthcare Policy and Innovation, Department of Medicine, University of Michigan, 2800 Plymouth Road, Building 10, Room G100, Ann Arbor, MI 48109-2800.

Dr. Langa: Institute for Healthcare Policy and Innovation, Institute of Gerontology, University of Michigan, 2800 Plymouth Road, Building 16, Room 444E, Ann Arbor, MI 48109-2800. Dr. Wright: Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.

Dr. Griggs: Division of Hematology and Oncology, Department of Medicine, and Health Management and Policy, School of Public Health, University of Michigan, 2800 Plymouth Road, Building 16, Room 116W, Ann Arbor, MI 48109-2800.

Author Contributions: Conception and design: J.A. Harris, E. Byhoff, C.R. Perumalswami, A.A. Wright, J.J. Griggs. Analysis and interpretation of the data: J.A. Harris, E. Byhoff, C.R. Perumalswami, K.M. Langa, A.A. Wright, J.J. Griggs. Drafting of the article: J.A. Harris, C.R. Perumalswami, A.A. Wright, J.J. Griggs.

Critical revision of the article for important intellectual content: J.A. Harris, E. Byhoff, C.R. Perumalswami, K.M. Langa, A.A. Wright, J.J. Griggs.

Final approval of the article: J.A. Harris, E. Byhoff, C.R. Perumalswami, K.M. Langa, A.A. Wright, J.J. Griggs.

Statistical expertise: J.A. Harris.

Administrative, technical, or logistic support: J.A. Harris. Collection and assembly of data: J.A. Harris, E. Byhoff, K.M. Langa.

APPENDIX: STATISTICAL MODEL SELECTION AND COMPOSITION

The statistical model development process began with a conceptual model of how obesity may affect end-of-life decision making. On the basis of the conceptual model, we selected from among the many variables available in the HRS to make an inclusive yet parsimonious selection of variables to include as confounders.

On the basis of the distributions of the dependent variables, we used 3 separate statistical models to properly describe dependent variables that were dichotomous (hospice enrollment and in-home death), continuous count data (number of days in hospice), and continuous and skewed data (total Medicare expenditures). On the basis of the known distributions, we chose generalized linear models with various response probability distributions and link functions: a binomial distribution and logit link for hospice enrollment and in-home death, a Poisson distribution and log link for total hospice days, and a gamma distribution and log link for expenditures.

The primary independent variable was BMI. In choosing the functional form that BMI would take in the

Annals.org

models, we first examined previous literature about how BMI affects health care outcomes. Although there are few data about health care use (most models treat it as a categorical variable), published literature about BMI and mortality described a nonlinear function form, second-order or higher (22, 54, 55).

Next, on the basis of our hypothesized relationship between the outcomes and BMI, we believed that BMI would approximate a functional quadratic form. Specifically, we believed that as BMI increased, there would be increasing challenges of prognostication for providers and perhaps family, as well as challenges in the use of home-based care or provision of hospice services. We did not expect these challenges to increase in a linear manner as BMI increased; rather, we expected the effect to be relatively constant for more severe BMI values.

We used the traditional World Health Organization BMI categories as the basis of our model, as part of a modified splines analysis, to examine the functional form of the outcomes in relation to BMI in a nonparametric form. As we noted in our sensitivity analysis using World Health Organization/National Institutes of Health BMI categories (Appendix Tables 5 and 6), this functional form is roughly quadratic, with an increasing relationship that levels off at the more severe BMI categories. We also explored the functional form of BMI as a cubic term to determine whether there was any advantage in terms of model fit when using higher-order forms of BMI.

To help choose the most appropriate functional form of BMI (categorical, linear, quadratic, or cubic), we examined the overall model fit, the calibration across deciles of predicted probabilities to ensure that the model had randomly distributed residuals (observed vs. predicted values), and its discrimination across the range of BMI values.

On the basis of this analysis, we used a quadratic functional form for our primary independent variable in the final models. We reported the mean predicted probability of the outcomes for the study sample when BMI was held at 5 levels (20, 25, 30, 35, or 40 kg/m²) and the rest of the variables were held at known values. We used the same quadratic functional form for BMI, regardless of the outcome, to allow the model to be as simple and understandable to readers as possible.

Our analysis also included 4 variations on the aforementioned statistical model and covariates. First, we examined the association of BMI and the predicted outcomes if an interaction term between the quadratic BMI term and the interval between the last survey and death was added to the full model. Second, we examined the association between BMI and the predicted outcomes if a covariate measuring cause of death was added to the full model. Third, we examined the association between BMI and the predicted outcomes if a


Λ.

covariate quantifying whether the survey proxy reported the decedent's death as "expected" was added to the full model. Finally, we included all available HRS decedents (including those who reported being in a nursing home at the last survey before death) to examine whether exclusion of these respondents led to substantial selection bias in the study sample.

Web-Only References

54. Flegal KM, Kit BK, Graubard BI. Body mass index categories in observational studies of weight and risk of death. Am J Epidemiol. 2014;180:288-96. [PMID: 24893710] doi:10.1093/aje/kwu111 55. Cao S, Moineddin R, Urquia ML, Razak F, Ray JG. J-shapedness: an often missed, often miscalculated relation: the example of weight and mortality. J Epidemiol Community Health. 2014;68:683-90. [PMID: 24683176] doi:10.1136/jech-2013-203439

Appendix Figure. Study flow diagram.



Appendix Table 1. Medical Comorbidities of Decedents, by BMI Category*

Congestive heart failure (18.5 kg/m²) (n = 424) (18.5-24.9 kg/m²) (n = 1763) (30-39.9 kg/m²) (n = 844) (≥40 kg/m²) (n = 117) Congestive heart failure 113 (27) 689 (27) 517 (29) 294 (34) 52 (44) Cardiac arrhythmia 114 (27) 778 (31) 518 (29) 234 (27) 29 (25) Valvular disease 56 (13) 317 (13) 209 (12) 107 (12) 14 (12) Pulmonary circulation disorder 14 (3) 104 (4) 91 (5) 49 (6) 19 (16) Peripheral vascular disorder 57 (13) 443 (18) 337 (19) 146 (17) 21 (18) Hypertension, uncomplicated 201 (47) 1323 (53) 1021 (58) 531 (61) 76 (65) Hypertension, complicated 48 (11) 313 (13) 238 (14) 149 (17) 21 (18) Paralysis ≤10 (≤2) 58 (2) 36 (2) 27 (3) ±10 (≤9) Other neurologic disorder 40 (9) 216 (9) 148 (8) 63 (7) ±10 (≤9) Chronic pulmonary disease 15 (43) 682 (27) 500 (28)	Comorbidity			BMI Category		
Cardiac arrhythmia 114 (27) 778 (31) 518 (29) 234 (27) 29 (25) Valvular disease 56 (13) 317 (13) 209 (12) 107 (12) 14 (12) Pulmonary circulation disorder 14 (3) 104 (4) 91 (5) 49 (6) 19 (16) Peripheral vascular disorder 57 (13) 443 (18) 337 (19) 146 (17) 21 (18) Hypertension, uncomplicated 201 (47) 1323 (53) 1021 (58) 531 (61) 76 (65) Hypertension, complicated 48 (11) 313 (13) 238 (14) 149 (17) 21 (18) Paralysis ≤10 (≤2) 58 (2) 36 (2) 27 (3) ≤10 (≤9) Other neurologic disorder 40 (9) 216 (9) 148 (8) 63 (7) ≤10 (≤9) Other neurologic disorder 40 (9) 216 (9) 148 (8) 63 (7) ≤10 (≤9) Other neurologic disorder 49 (50) 549 (31) 384 (44) 68 (58) Diabetes, uncomplicated 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, uncomplicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) <t< th=""><th></th><th>(<18.5 kg/m²)</th><th>(18.5-24.9 kg/m²)</th><th>(25-29.9 kg/m²)</th><th>(30-39.9 kg/m²)</th><th></th></t<>		(<18.5 kg/m²)	(18.5-24.9 kg/m ²)	(25-29.9 kg/m ²)	(30-39.9 kg/m ²)	
Valvular disease 56 (13) 317 (13) 209 (12) 107 (12) 14 (12) Pulmonary circulation disorder 14 (3) 104 (4) 91 (5) 49 (6) 19 (16) Peripheral vascular disorder 57 (13) 443 (18) 337 (19) 146 (17) 21 (18) Hypertension, uncomplicated 201 (47) 1323 (53) 1021 (58) 531 (61) 76 (65) Hypertension, complicated 48 (11) 313 (13) 238 (14) 149 (17) 21 (18) Paralysis ≤10 (≤2) 58 (2) 36 (2) 27 (3) ≤10 (≤9) Other neurologic disorder 40 (9) 216 (9) 148 (8) 63 (7) ≤10 (≤9) Chronic pulmonary disease 154 (36) 682 (27) 500 (28) 265 (31) 47 (40) Diabetes, uncomplicated 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, uncomplicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyriodism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) </td <td>Congestive heart failure</td> <td>113 (27)</td> <td>689 (27)</td> <td>517 (29)</td> <td>294 (34)</td> <td>52 (44)</td>	Congestive heart failure	113 (27)	689 (27)	517 (29)	294 (34)	52 (44)
Pulmonary circulation disorder 14 (3) 104 (4) 91 (5) 49 (6) 19 (16) Peripheral vascular disorder 57 (13) 443 (18) 337 (19) 146 (17) 21 (18) Hypertension, uncomplicated 201 (47) 1323 (53) 1021 (58) 531 (61) 76 (65) Hypertension, complicated 48 (11) 313 (13) 238 (14) 149 (17) 21 (18) Paralysis ≤10 (≤2) 58 (2) 36 (2) 27 (3) ≤10 (≤9) Other neurologic disorder 40 (9) 216 (9) 148 (8) 63 (7) ≤10 (≤9) Other neurologic disorder 40 (9) 216 (9) 148 (8) 63 (7) ≤10 (≤9) Other neurologic disorder 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, uncomplicated 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, uncomplicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) Renal failure 48 (11) 320 (13) 259 (15) 158 (18) 33 (28) Liver disease ≤10 (≤2) 76 (3) 72 (4) 37 (4) ≤10 (≤9) Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) ≤10 (≤9) Lymphoma ≤10 (≤2) 57 (2) 46 (3) 18 (2) ≤10 (≤9) Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 78 (3) 53 (3) 14 (2) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 50 (3) 23 (3) ≤10 (≤9) Psychosis	Cardiac arrhythmia	114 (27)	778 (31)	518 (29)	234 (27)	29 (25)
Peripheral vascular disorder 57 (13) 443 (18) 337 (19) 146 (17) 21 (18) Hypertension, uncomplicated 201 (47) 1323 (53) 1021 (58) 531 (61) 76 (65) Hypertension, complicated 48 (11) 313 (13) 238 (14) 149 (17) 21 (18) Paralysis ≤10 (≤2) 58 (2) 36 (2) 27 (3) ≤10 (≤9) Other neurologic disorder 40 (9) 216 (9) 148 (8) 63 (7) ≤10 (≤9) Chronic pulmonary disease 154 (36) 682 (27) 500 (28) 265 (31) 47 (40) Diabetes, uncomplicated 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, complicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) Renal failure 48 (11) 320 (13) 259 (15) 158 (18) 33 (28) Liver disease ≤10 (≤2) 76 (3) 72 (4) 37 (4) ≤10 (≤9)	Valvular disease	56 (13)	317 (13)	209 (12)	107 (12)	14 (12)
Hypertension, uncomplicated 201 (47) 1323 (53) 1021 (58) 531 (61) 76 (65) Hypertension, complicated 48 (11) 313 (13) 238 (14) 149 (17) 21 (18) Paralysis ≤10 (≤2) 58 (2) 36 (2) 27 (3) ≤10 (≤9) Chronic pulmonary disease 40 (9) 216 (9) 148 (8) 63 (7) ≤10 (≤9) Chronic pulmonary disease 154 (36) 682 (27) 500 (28) 265 (31) 47 (40) Diabetes, uncomplicated 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, complicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) Renal failure 48 (11) 320 (13) 259 (15) 158 (18) 33 (28) Liver disease ≤10 (≤2) 76 (3) 72 (4) 37 (4) ≤10 (≤9) Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) ≤10 (≤9) Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) ≤10 (≤9) Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 78 (3) 53 (3) 14 (2) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Flychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9) Flychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9) Flychosis	Pulmonary circulation disorder	14 (3)	104 (4)	91 (5)	49 (6)	19 (16)
Hypertension, complicated 48 (11) 313 (13) 238 (14) 149 (17) 21 (18) Paralysis ≤10 (≤2) 58 (2) 36 (2) 27 (3) ≤10 (≤9) Other neurologic disorder 40 (9) 216 (9) 148 (8) 63 (7) ≤10 (≤9) Chronic pulmonary disease 154 (36) 682 (27) 500 (28) 265 (31) 47 (40) Diabetes, uncomplicated 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, complicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) Renal failure 48 (11) 320 (13) 259 (15) 158 (18) 33 (28) Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) ≤10 (≤9) Lymphoma ≤10 (≤2) 57 (2) 46 (3) 18 (2) ≤10 (≤9) Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) ≤10 (≤9) Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9) Psychosis	Peripheral vascular disorder	57 (13)	443 (18)	337 (19)	146 (17)	21 (18)
Paralysis ≤10 (≤2) 58 (2) 36 (2) 27 (3) ≤10 (≤9) Other neurologic disorder 40 (9) 216 (9) 148 (8) 63 (7) ≤10 (≤9) Chronic pulmonary disease 154 (36) 682 (27) 500 (28) 265 (31) 47 (40) Diabetes, uncomplicated 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, complicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) Renal failure 48 (11) 320 (13) 259 (15) 158 (18) 33 (28) Liver disease ≤10 (≤2) 76 (3) 72 (4) 37 (4) ≤10 (≤9) Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) ≤10 (≤9) Lymphoma ≤10 (≤2) 57 (2) 46 (3) 18 (2) ≤10 (≤9) Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) ≤10 (≤9) Solid tumor without metasta	Hypertension, uncomplicated	201 (47)	1323 (53)	1021 (58)	531 (61)	76 (65)
Other neurologic disorder 40 (9) 216 (9) 148 (8) 63 (7) ≤10 (≤9) Chronic pulmonary disease 154 (36) 682 (27) 500 (28) 265 (31) 47 (40) Diabetes, uncomplicated 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, complicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) Renal failure 48 (11) 320 (13) 259 (15) 158 (18) 33 (28) Liver disease ≤10 (≤2) 76 (3) 72 (4) 37 (4) ≤10 (≤9) Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) ≤10 (≤9) Lymphoma ≤10 (≤2) 57 (2) 46 (3) 18 (2) ≤10 (≤9) Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) ≤10 (≤9) Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5	Hypertension, complicated	48 (11)	313 (13)	238 (14)	149 (17)	21 (18)
Chronic pulmonary disease 154 (36) 682 (27) 500 (28) 265 (31) 47 (40) Diabetes, uncomplicated 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, complicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) Renal failure 48 (11) 320 (13) 259 (15) 158 (18) 33 (28) Liver disease ≤10 (≤2) 76 (3) 72 (4) 37 (4) ≤10 (≤9) Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) ≤10 (≤9) Lymphoma ≤10 (≤2) 57 (2) 46 (3) 18 (2) ≤10 (≤9) Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) ≤10 (≤9) Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5)	Paralysis	≤10 (≤2)	58 (2)	36 (2)	27 (3)	≤10 (≤9)
Diabetes, uncomplicated 39 (9) 495 (20) 549 (31) 384 (44) 68 (58) Diabetes, complicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) Renal failure 48 (11) 320 (13) 259 (15) 158 (18) 33 (28) Liver disease ≤10 (≤2) 76 (3) 72 (4) 37 (4) ≤10 (≤9) Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) ≤10 (≤9) Lymphoma ≤10 (≤2) 57 (2) 46 (3) 18 (2) ≤10 (≤9) Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) ≤10 (≤9) Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9)	Other neurologic disorder	40 (9)	216 (9)	148 (8)	63 (7)	≤10 (≤9)
Diabetes, complicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) Renal failure 48 (11) 320 (13) 259 (15) 158 (18) 33 (28) Liver disease ≤10 (≤2) 76 (3) 72 (4) 37 (4) ≤10 (≤9) Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) ≤10 (≤9) Lymphoma ≤10 (≤2) 57 (2) 46 (3) 18 (2) ≤10 (≤9) Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) ≤10 (≤9) Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (Chronic pulmonary disease	154 (36)	682 (27)	500 (28)	265 (31)	47 (40)
Diabetes, complicated 11 (3) 183 (7) 225 (13) 153 (18) 33 (28) Hypothyroidism 66 (16) 305 (12) 199 (11) 108 (13) 19 (16) Renal failure 48 (11) 320 (13) 259 (15) 158 (18) 33 (28) Liver disease ≤10 (≤2) 76 (3) 72 (4) 37 (4) ≤10 (≤9) Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) ≤10 (≤9) Lymphoma ≤10 (≤2) 57 (2) 46 (3) 18 (2) ≤10 (≤9) Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) ≤10 (≤9) Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (Diabetes, uncomplicated	39 (9)	495 (20)	549 (31)	384 (44)	68 (58)
Renal failure	Diabetes, complicated	11 (3)	183 (7)	225 (13)	153 (18)	33 (28)
Liver disease $\leq 10 (\leq 2)$ 76 (3) 72 (4) 37 (4) $\leq 10 (\leq 9)$ Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) $\leq 10 (\leq 9)$ Lymphoma $\leq 10 (\leq 2)$ 57 (2) 46 (3) 18 (2) $\leq 10 (\leq 9)$ Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) $\leq 10 (\leq 9)$ Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) $\leq 10 (\leq 9)$ Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) $\leq 10 (\leq 9)$ Weight loss 67 (16) 200 (8) 79 (4) 41 (5) $\leq 10 (\leq 9)$ Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia $\leq 10 (\leq 2)$ 78 (3) 53 (3) 14 (2) $\leq 10 (\leq 9)$ Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse $\leq 10 (\leq 2)$ 38 (2) 32 (2) 14 (2) $\leq 10 (\leq 9)$ Psychosis 12 (3) 78 (3) 50 (3) 23 (3) $\leq 10 (\leq 9)$	Hypothyroidism	66 (16)	305 (12)	199 (11)	108 (13)	19 (16)
Liver disease $\leq 10 (\leq 2)$ 76 (3) 72 (4) 37 (4) $\leq 10 (\leq 9)$ Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) $\leq 10 (\leq 9)$ Lymphoma $\leq 10 (\leq 2)$ 57 (2) 46 (3) 18 (2) $\leq 10 (\leq 9)$ Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) $\leq 10 (\leq 9)$ Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) $\leq 10 (\leq 9)$ Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) $\leq 10 (\leq 9)$ Weight loss 67 (16) 200 (8) 79 (4) 41 (5) $\leq 10 (\leq 9)$ Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia $\leq 10 (\leq 2)$ 78 (3) 53 (3) 14 (2) $\leq 10 (\leq 9)$ Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse $\leq 10 (\leq 2)$ 38 (2) 32 (2) 14 (2) $\leq 10 (\leq 9)$ Psychosis 12 (3) 78 (3) 50 (3) 23 (3) $\leq 10 (\leq 9)$	Renal failure	48 (11)	320 (13)	259 (15)	158 (18)	33 (28)
Peptic ulcer disease, excluding bleeding 13 (3) 44 (2) 27 (2) 11 (1) ≤10 (≤9) Lymphoma ≤10 (≤2) 57 (2) 46 (3) 18 (2) ≤10 (≤9) Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) ≤10 (≤9) Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 78 (3) 53 (3) 14 (2) ≤10 (≤9) Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Liver disease	≤10 (≤2)	76 (3)	72 (4)	37 (4)	≤10 (≤9)
Metastatic cancer 19 (4) 147 (6) 143 (8) 61 (7) ≤10 (≤9) Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 78 (3) 53 (3) 14 (2) ≤10 (≤9) Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Peptic ulcer disease, excluding bleeding	13 (3)	44 (2)	27 (2)	11 (1)	≤10 (≤9)
Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Cagulopathy 20 (5) 153 (6) 114 (6) 46 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 78 (3) 53 (3) 14 (2) ≤10 (≤9) Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Lymphoma	≤10 (≤2)	57 (2)	46 (3)	18 (2)	≤10 (≤9)
Solid tumor without metastasis 66 (16) 470 (19) 384 (22) 164 (19) 15 (13) Rheumatoid arthritis/collagen disorder 20 (5) 112 (4) 81 (5) 43 (5) ≤10 (≤9) Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 78 (3) 53 (3) 14 (2) ≤10 (≤9) Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Metastatic cancer	19 (4)	147 (6)	143 (8)	61 (7)	≤10 (≤9)
Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 78 (3) 53 (3) 14 (2) ≤10 (≤9) Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Solid tumor without metastasis	66 (16)		384 (22)	164 (19)	
Coagulopathy 20 (5) 153 (6) 114 (6) 46 (5) ≤10 (≤9) Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 78 (3) 53 (3) 14 (2) ≤10 (≤9) Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Rheumatoid arthritis/collagen disorder	20 (5)	112 (4)	81 (5)	43 (5)	≤10 (≤9)
Weight loss 67 (16) 200 (8) 79 (4) 41 (5) ≤10 (≤9) Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 78 (3) 53 (3) 14 (2) ≤10 (≤9) Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Coagulopathy		153 (6)	114 (6)	46 (5)	
Fluid and electrolyte disorders 111 (26) 546 (22) 343 (19) 194 (22) 26 (22) Blood loss anemia ≤10 (≤2) 78 (3) 53 (3) 14 (2) ≤10 (≤9) Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Weight loss				41 (5)	≤10 (≤9)
Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Fluid and electrolyte disorders		546 (22)			26 (22)
Iron deficiency anemia 53 (13) 251 (10) 164 (9) 94 (11) 17 (15) Alcohol abuse ≤10 (≤2) 38 (2) 32 (2) 14 (2) ≤10 (≤9) Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Blood loss anemia	, ,	` '	, ,	, ,	, ,
Alcohol abuse $\leq 10 (\leq 2)$ 38 (2) 32 (2) 14 (2) $\leq 10 (\leq 9)$ Psychosis 12 (3) 78 (3) 50 (3) 23 (3) $\leq 10 (\leq 9)$	Iron deficiency anemia					
Psychosis 12 (3) 78 (3) 50 (3) 23 (3) ≤10 (≤9)	Alcohol abuse	, ,		, ,		
	Psychosis	, ,				
	Depression					

BMI = body mass index.

^{*} Values are numbers (percentages). Values based on ≤10 participants were assigned a value of ≤10 because of privacy restrictions.

Appendix Table 2. Predicted Total In-Home Hospice Days and Total Out-of-Home Hospice Days, by BMI $(n = 1971)^*$

Predicted End-of-Life Outcome	вмі					
	20 kg/m ²	25 kg/m²	30 kg/m²	35 kg/m²	40 kg/m²	
Mean predicted total in-home hospice days (95% CI)	42.0 (41.6 to 42.4)	39.5 (39.2 to 39.9)	38.0 (37.6 to 38.5)	37.4 (36.8 to 38.1)	37.7 (36.4 to 39.0)	
Difference vs. BMI of 20 kg/m ²	Reference	-2.5 (-2.9 to -2.1)	-4.0 (-4.6 to -3.4)	-4.6 (-5.5 to -3.7)	-4.4 (-5.8 to -3.0)	
Mean predicted total out-of-home hospice days (95% CI)	0.7 (0.6 to 0.8)	0.9 (0.8 to 0.9)	0.9 (0.8 to 1.0)	0.9 (0.8 to 1.0)	0.8 (0.6 to 1.0)	
Difference vs. BMI of 20 kg/m ²	Reference	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.1 (-0.1 to 0.3)	

BMI = body mass index.

^{**}Predicted numbers of hospice days were calculated for representative BMI values and were adjusted for decedent age, race/ethnicity, marital status, 28 Elixhauser medical conditions, total household assets, number of activities of daily living and instrumental activities of daily living cognitive function (normal, mild cognitive impairment/cognitive impairment, no dementia, or dementia), quintile of regional end-of-life expenditures, and year of death.

Appendix Table 3. Causes of Death and Proxy-Reported Expected Death, by BMI Cate	gory*
--	-------

Characteristic	BMI Category					
	Underweight (<18.5 kg/m ²) (n = 424)	Normal (18.5-24.9 kg/m²) (n = 2509)	Overweight (25-29.9 kg/m²) (n = 1763)	Obese (30-39.9 kg/m²) (n = 864)	Morbidly Obese (≥40 kg/m²) (n = 117)	
Cause of death, n (%)						
Cardiac	131 (31)	812 (32)	576 (33)	290 (34)	25 (21)	
Malignancy	74 (17)	507 (20)	392 (22)	176 (20)	20 (17)	
Pulmonary	67 (16)	262 (10)	138 (8)	56 (6)	12 (10)	
Diabetes	≤10 (≤2)	51 (2)	46 (3)	41 (5)	≤10 (≤9)	
Neurologic	11 (3)	91 (4)	38 (2)	≤20 (2)	≤10 (≤9)	
Renal	≤10 (≤2)	46 (2)	29 (2)	26 (2)	≤10 (≤9)	
General infectious disease	≤10 (≤2)	34 (2)	37 (2)	≤20 (2)	≤10 (≤9)	
Gastrointestinal/hepatic	≤10 (≤2)	13 (1)	18 (1)	≤10 (1)	≤10 (≤9)	
Other	71 (17)	367 (15)	240 (14)	102 (12)	≤10 (≤9)	
Unknown	42 (10)	326 (13)	249 (14)	133 (15)	29 (25)	
Proxy-reported expected deaths, n (%)						
Yes	263 (62)	1369 (55)	899 (51)	384 (44)	53 (45)	
No	133 (32)	931 (37)	702 (40)	388 (45)	≤60 (≤51)	
Unknown	28 (6)	209 (8)	162 (9)	92 (10)	≤10 (≤8)	

BMI = body mass index.

a Values based on ≤10 participants were assigned a value of ≤10 because of privacy restrictions. In the case of a single cell in a column being suppressed, the cells with the second- and/or third-lowest count were also assigned a value of less than the nearest multiple of 10 to prevent the ability to calculate the value of the suppressed cell. Percentages may not sum to 100 due to rounding.

Appendix Table 4. Predicted Probability of Hospice Enrollment, Total Hospice Days, and Probability of In-Home Death, by BMI, With Additional Model Covariate for Cause of Death, Expected Death, or Interaction Between Measured BMI and Time From Survey to Death*

Predicted End-of-Life Outcome			ВМІ		
	20 kg/m ²	25 kg/m ²	30 kg/m²	35 kg/m²	40 kg/m ²
Original model with addition of "cause of death" covariate (n = 4897)					
Predicted probability of hospice enrollment, %	36.2 (34.4 to 38.0)	33.6 (32.3 to 35.0)	30.2 (28.4 to 32.0)	26.2 (23.7 to 28.6)	21.7 (18.0 to 25.5)
Difference vs. BMI of 20 kg/m²	Reference	-2.6 (-4.4 to -0.9)	-6.0 (-8.7 to -3.3)	-10.1 (-13.5 to -6.7)	-14.5 (-19.0 to -10.0
Predicted total hospice days	42.2 (41.7 to 42.6)	40.5 (40.1 to 40.9)	39.0 (38.4 to 39.5)	37.6 (36.8 to 38.3)	36.3 (34.9 to 37.7)
Difference vs. BMI of 20 kg/m ²	Reference	-1.7 (-2.1 to -1.2)	-3.2 (-3.9 to -2.5)	-4.6 (-5.6 to -3.6)	-5.9 (-7.4 to -4.3)
Predicted probability of in-home death, %	60.0 (58.0 to 62.0)	58.4 (56.9 to 59.8)	56.8 (54.8 to 58.8)	55.3 (52.5 to 58.2)	54.0 (49.8 to 58.2)
Difference vs. BMI of 20 kg/m ²	Reference	-1.7 (-3.5 to 0.1)	-3.3 (-6.3 to -0.3)	-4.7 (-8.7 to -0.8)	−6.0 (−11.2 to −0.9)
Original model with addition of "expected death" covariate (n = 5194)					
Predicted probability of hospice enrollment, %	36.9 (35.2 to 38.7)	34.9 (33.5 to 36.2)	31.9 (30.2 to 33.7)	28.3 (25.9 to 30.7)	24.1 (20.3 to 27.9)
Difference vs. BMI of 20 kg/m ²	Reference	-2.1 (-3.8 to -0.4)	-5.0 (-7.6 to -2.4)	-8.6 (-11.9 to -5.2)	-12.8 (-17.3 to -8.3)
Predicted total hospice days	43.1 (42.7 to 43.6)	41.0 (40.6 to 41.4)	39.1 (38.6 to 39.6)	37.5 (36.7 to 38.2)	36.0 (34.7 to 37.3)
Difference vs. BMI of 20 kg/m ²	Reference	−2.1 (−2.6 to −1.7)	-4.0 (-4.7 to -3.3)	-5.7 (-6.6 to -4.7)	-7.1 (-8.5 to -5.7)
Predicted probability of in-home death, %	60.7 (58.7 to 62.6)	59.0 (57.6 to 60.4)	57.4 (55.4 to 59.4)	55.9 (53.1 to 58.7)	54.5 (50.4 to 58.6)
Difference vs. BMI of 20 kg/m ²	Reference	-1.7 (-3.4 to 0.1)	-3.3 (-6.2 to -0.3)	-4.8 (-8.7 to -0.9)	-6.2 (-11.3 to -1.1)
Original model with addition of interaction term between BMI and time from survey to death (n = 5677)					
Predicted probability of hospice enrollment, %	38.3 (36.5 to 40.2)	35.3 (33.9 to 36.6)	31.6 (29.9 to 33.3)	27.4 (25.0 to 29.7)	22.8 (19.3 to 26.4)
Difference vs. BMI of 20 kg/m ²	Reference	-3.1 (-1.3 to 4.8)	-6.8 (-9.4 to -4.1)	-11.0 (-14.3 to -7.6)	-15.5 (-19.8 to -11.2
Predicted total hospice days	43.8 (43.4 to 44.2)	40.3 (40.0 to 40.6)	38.4 (38.0 to 38.8)	37.8 (37.1 to 38.4)	38.6 (37.3 to 39.9)
Difference vs. BMI of 20 kg/m ²	Reference	-3.5 (-3.9 to -3.0)	-5.4 (-6.1 to -4.7)	-6.0 (-6.9 to -5.1)	−5.2 (−6.6 to −3.7)
Predicted probability of in-home death, %	61.1 (59.2 to 63.0)	59.8 (58.4 to 61.1)	58.2 (56.3 to 60.1)	56.4 (53.8 to 59.1)	54.4 (50.4 to 58.4)
Difference vs. BMI of 20 kg/m ²	Reference	-1.3 (-3.1 to 0.4)	-2.9 (-5.8 to 0.0)	-4.7 (-8.4 to -0.9)	−6.7 (−11.6 to −1.8)

BMI = body mass index.

^{**}Predicted probabilities and predicted numbers of hospice days were calculated for representative BMI values and were adjusted for decedent age, race/ethnicity, marital status, 28 Elixhauser medical conditions, total household assets, number of activities of daily living and instrumental activities of daily living, cognitive function, quintile of regional end-of-life expenditures, and year of death. Values are means (95% CIs).

Appendix Table 5. Predicted Probability of Hospice Enrollment, Total Hospice Days, Probability of In-Home Death, and Total Medicare Expenditures, by 4 Categories of BMI $(n = 5677)^*$

Predicted End-of-Life BMI Category Outcome				
outome.	Underweight (<18.5 kg/m²) (n = 424)	Normal (18.5-24.9 kg/m²) (n = 2509)	Overweight (25-29.9 kg/m²) (n = 1763)	Obese (≥30 kg/m²) (n = 981)
Mean probability of hospice enrollment (95% CI), %	39.3 (34.9 to 43.8)	37.0 (35.2 to 38.8)	34.2 (32.1 to 36.3)	27.8 (25.0 to 30.5)
Difference vs. normal BMI	-2.3 (-7.1 to 2.5)	Reference	−2.9 (−5.7 to −0.1)	−9.2 (−12.6 to −5.9)
Mean total hospice days (95% CI)†	47.1 (46.1 to 48.2)	40.5 (40.1 to 40.9)	41.7 (41.2 to 42.2)	37.6 (36.8 to 38.4)
Difference vs. normal BMI	6.6 (5.5 to 7.7)	Reference	1.2 (0.5 to 1.9)	-3.0 (-3.9 to -2.0)
Mean probability of in-home death (95% CI), %	61.5 (56.8 to 66.2)	60.8 (58.9 to 62.7)	58.8 (56.6 to 61.1)	57.1 (53.9 to 60.3)
Difference vs. normal BMI	0.7 (-4.3 to 5.7)	Reference	-1.9 (-4.9 to 1.1)	-3.7 (-7.5 to 0.1)
Mean total Medicare expenditures (95% CI), \$	40 463 (36 625 to 44 301)	44 005 (42 269 to 45 742)	45 755 (43 668 to 47 843)	45 283 (42 494 to 48 073)
Difference vs. normal BMI	-3542 (-7631 to 546)	Reference	1750 (-905 to 4405)	1278 (-2068 to 4624)

BMI = body mass index.

* Adjusted for decedent age, race/ethnicity, marital status, 28 Elixhauser medical conditions, total household assets, number of activities of daily living and instrumental activities of daily living, cognitive function, quintile of regional end-of-life expenditures, and year of death. † Among decedents who were ever enrolled in hospice (n = 1971).

Appendix Table 6. Predicted Probability of Hospice Enrollment, Total Hospice Days, Probability of In-Home Death, and Total Medicare Expenditures, by 6 Categories of BMI $(n = 5677)^*$

Predicted End-of-Life			BMI Category	tegory		
	Underweight $(<18.5 \text{ kg/m}^2)$ $(n = 424)$	Normal $(18.5-24.9 \text{ kg/m}^2)$ $(n = 2509)$	Overweight (25-29.9 kg/m ²) $(n = 1763)$	Class I Obesity (30-34.9 kg/m ²) ($n = 628$)	Class II Obesity (35-39.9 kg/m ²) $(n = 236)$	Class III Obesity $(\geq 40 \text{ kg/m}^2)$ $(n = 117)$
Mean probability of hospice enrollment (95% CI), %	39.4 (34.9 to 43.8)	37.1 (35.3 to 38.8)	34.2 (32.1 to 36.3)	28.6 (25.3 to 32.0)	27.6 (22.1 to 33.0)	22.9 (15.5 to 30.3)
Difference vs. normal BMI	2.3 (-2.5 to 7.1)	Reference	-2.9(-5.7 to -0.1)	-8.4 (-12.3 to -4.5)	-9.5 (-15.3 to -3.7)	-14.2 (-21.9 to -6.5)
Mean total hospice days (95% CI)†	47.1 (46.0 to 48.1)	40.5 (40.1 to 40.9)	41.7 (41.1 to 42.2)	38.4 (37.5 to 39.4)	32.8 (31.3 to 34.2)	44.4 (41.8 to 47.0)
Difference vs. normal BMI	6.6 (5.4 to 7.7)	Reference	1.2 (0.5 to 1.9)	-2.1(-3.2 to -1.1)	-7.8 (-9.3 to -6.3)	3.9 (1.2 to 6.6)
Mean probability of in-home death (95% CI), %	61.5 (56.8 to 66.2)	60.8 (58.9 to 62.7)	58.8 (56.6 to 61.1)	57.5 (53.6 to 61.3)	59.3 (53.0 to 65.5)	50.0 (40.9 to 59.2)
Difference vs. normal BMI	0.7 (-4.3 to 5.7)	Reference	-2.0 (-5.0 to 1.0)	-3.3 (-7.7 to 1.0)	-1.5 (-8.1 to 5.1)	-10.8 (-20.2 to -1.4)
Mean total end-of-life expenditures (95% CI), \$	40 453 (36 617 to 44 288)	44 007 (42 271 to 45 743)	45 761 (43 674 to 47 848)	45 920 (42 460 to 49 380)	42 334 (37 134 to 47 533)	47 837 (39 474 to 56 200)
Difference vs. normal BMI	-3555 (-7640 to 531)	Reference	1754 (-900 to 4408)	1913 (-1985 to 5811)	-1674 (-7207 to 3860)	3830 (-4778 to 12437)

BMI = body mass index.
* Adjusted for decedent age, race/ethnicity, marital status, 28 Elixhauser medical conditions, total household assets, number of activities of daily living and instrumental activities of daily living, cognitive function, quintile of regional end-of-life expenditures, and year of death.
† Among decedents who were ever enrolled in hospice (n = 1971).

Appendix Table 7. Predicted Probability of Hospice Enrollment, Total Hospice Days, Probability of In-Home Death, and Total Medicare Expenditures, by BMI, in the Full Available Population (n = 6975)*

Outcome			BMI		
	20 kg/m ²	25 kg/m²	30 kg/m²	35 kg/m²	40 kg/m ²
Predicted probability of hospice enrollment, %	37.7 (36.2 to 39.3)	35.3 (34.1 to 36.6)	32.1 (30.5 to 33.7)	28.3 (26.1 to 30.5)	24.1 (20.7 to 27.4)
Difference vs. BMI of 20 kg/m²	Reference	-2.4 (-3.9 to -0.9)	-5.6 (-7.9 to -3.3)	-9.4 (-12.4 to -6.4)	-13.7 (-17.7 to -9.7)
Predicted total hospice days†	46.5 (46.1 to 46.9)	42.8 (42.5 to 43.1)	40.6 (40.2 to 41.0)	39.8 (39.1 to 40.4)	40.1 (39.0 to 41.3)
Difference vs. BMI of 20 kg/m^2	Reference	-3.7 (-4.1 to -3.3)	-5.9 (-6.4 to -5.3)	-6.7 (-7.5 to -5.9)	-6.4 (-7.7 to -5.1)
Predicted probability of in-home death, %	62.8 (62.2 to 64.5)	61.4 (60.2 to 62.7)	60.0 (58.3 to 61.7)	58.5 (56.1 to 60.9)	57.1 (53.5 to 60.7)
Difference vs. BMI of 20 kg/m ²	Reference	-1.4 (-2.9 to 0.1)	-2.9(-5.3 to -0.4)	-4.3 (-7.6 to -1.0)	-5.8 (-10.0 to -1.5)
Predicted total end-of-life expenditures, \$	41 533 (40 050 to 43 016)	42 705 (41 556 to 43 855)	43 444 (41 945 to 44 943)	43 726 (41 684 to 45 768)	43 543 (40 509 to 46 576)
Difference vs. BMI of $20 \mathrm{kg/m^2}$	Reference	1172 (-89 to 2433)	1911 (-208 to 4030)	2193 (-601 to 4987)	2009 (-1676 to 5695)

BMI = body mass index.

* Predicted probabilities were calculated for representative BMI values and were adjusted for decedent age, race/ethnicity, marital status, 28 Elixhauser medical conditions, total household assets, limitations in activities of daily living and instrumental activities of daily living, cognitive function, quintile of regional end-of-life expenditures, and year of death. This cohort includes 5677 community-dwelling decedents and 1298 nursing home-dwelling decedents. These totals exclude 345 community-dwelling decedents and 54 nursing home-dwelling decedents who were excluded from the study cohort because of missing covariate data. Values are means (95% CIs).

† Among decedents who were ever enrolled in hospice (n = 2412).

Appendix Table 8. Coefficients, SEs, and Constant for Statistical Model Predicting Hospice Enrollment

Statistical Model Fredicting Flospice Li	monnent	
Covariate	Coefficient	SE
Body mass index	0.006	0.033
Body mass index (squared)	-0.001	0.001
Congestive heart failure Cardiac arrhythmia	-0.031 -0.145	0.080
Valvular disease	0.215	0.075
Pulmonary circulation disorder	0.164	0.147
Peripheral vascular disorder	-0.086	0.083
Hypertension, uncomplicated	0.046	0.068
Hypertension, complicated	-0.119	0.112
Paralysis Other neurologic disorder	0.091 0.236	0.205 0.111
Chronic pulmonary disease	0.038	0.072
Diabetes, uncomplicated	0.094	0.082
Diabetes, complicated	-0.004	0.119
Hypothyroidism	-0.068	0.094
Renal failure	0.094	0.111
Liver disease Peptic ulcer disease, excluding bleeding	0.402 -0.024	0.172
Lymphoma	0.646	0.234
Metastatic cancer	0.948	0.140
Solid tumor without metastasis	0.940	0.087
Rheumatoid arthritis/collagen disorder	-0.223	0.150
Coagulopathy	-0.004	0.130
Weight loss Fluid and electrolyte disorders	-0.032 0.100	0.124
Blood loss anemia	-0.303	0.004
Iron deficiency anemia	-0.017	0.106
Alcohol abuse	-0.086	0.249
Psychosis	0.064	0.181
Depression	0.024	0.104
Female sex	0.178	0.069
Age at death Race	0.019	0.004
White	_	_
Black	-0.605	0.099
Hispanic ethnicity	-0.280	0.150
Other	-0.301	0.195
Marital status		
Married Never married	- -0.617	0.207
Widowed	-0.002	0.075
Separated/divorced	-0.132	0.119
Quintile of regional end-of-life expenditures		
1	-	-
2 3	-0.177	0.107
4	-0.151 0.177	0.103
5	-0.330	0.100
Activities of daily living	0.000	0.100
0	=	-
1	0.029	0.090
2	0.119	0.104
3 4	-0.116 0.257	0.129 0.142
5	0.274	0.142
6	0.303	0.156
Instrumental activities of daily living		
0	-	-
1	-0.035	0.093
2 3	0.055 0.063	0.115 0.146
4	0.106	0.146
5	0.432	0.162
Cognitive function		
Normal cognitive function	-	-
Mild cognitive impairment/cognitive impairment or no dementia	0.130	0.075
Dementia	0.046	0.099
Total household wealth per 1 U.S. dollar	< 0.001	< 0.001
Year of death	0.111	0.008
Constant	-223.9	15.332